Viz.ai, a leader in artificial intelligence (AI)-powered disease detection and care coordination, has entered into a multi-year partnership with global pharmaceutical company, Bristol Myers Squibb (BMS), to deploy an AI algorithm and provider workflow software (Viz HCM) to help identify and triage patients who may require further evaluation for detecting hypertrophic cardiomyopathy (HCM).
HCM is the most common genetic heart abnormality. It causes muscles to become thickened, making it difficult for the heart to pump blood at a normal rate. The condition has few outwardly visible symptoms, often going undiagnosed for years.
According to the company, Viz HCM is intended to automatically review routine electrocardiograms (ECGs) from across a health system, to detect suspected cases of HCM and notify the appropriate cardiologist. Physicians can then review the ECG and take clinical action in a more timely manner, including recommending follow-up tests. Viz HCM will be integrated into the Viz.ai Cardio Suite for U.S. hospitals. The Viz.ai Intelligent Care Coordination Platform, which includes Viz.ai Cardio Suite, is adopted by approximately 1,300 hospitals in the U.S.
Suhas Krishna, Vice President, Head of Digital Health Product Management, Bristol Myers Squibb, stated in the Viz.ai press release, “At Bristol Myers Squibb, we believe that the use of AI to detect key, subtle characteristics in biosignals to aid physicians in the screening, diagnosis, treatment, and monitoring of diseases will have a critical and positive impact on patients’ lives. We are excited to continue building momentum in our support of Viz.ai’s research and development program. The speed and quality in which this novel AI algorithm and workflow sequencing product was designed, verified, validated, and submitted by Viz.ai for agency review is testament to the ability to drive rapid and meaningful innovation in health care.”
Click here to read the original news story.